Kurt I Kamrud

Summary

Affiliation: North Carolina
Country: USA

Publications

  1. ncbi In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs
    Kurt I Kamrud
    AlphaVax, Inc, Research Triangle Park, North Carolina 27709, USA
    J Virol 84:7713-25. 2010
  2. ncbi Alphavirus replicon approach to promoterless analysis of IRES elements
    K I Kamrud
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709 0307, USA
    Virology 360:376-87. 2007
  3. ncbi Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle
    K I Kamrud
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709, USA
    J Gen Virol 91:1723-7. 2010
  4. ncbi Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats
    Kurt I Kamrud
    AlphaVax, Inc, Research Triangle Park, North Carolina, United States of America
    PLoS ONE 3:e2709. 2008
  5. ncbi Development and preclinical evaluation of an alphavirus replicon vaccine for influenza
    Bolyn Hubby
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709, USA
    Vaccine 25:8180-9. 2007
  6. ncbi Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine
    Ryan L Vander Veen
    Harrisvaccines, Inc, Ames, IA 50010, USA
    Vaccine 30:1944-50. 2012
  7. ncbi Alphavirus vectors and vaccination
    Jonathan O Rayner
    AlphaVax, Inc, P O Box 110307, Research Triangle Park, NC 27709 0307, USA
    Rev Med Virol 12:279-96. 2002
  8. ncbi Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells
    Kevin P Nishimoto
    Molecular Biology and Biochemistry, School of Medicine, School of Biological Sciences, University of California, Irvine, Irvine, California 92697, USA
    Viral Immunol 20:88-104. 2007
  9. ncbi Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model
    Edward L Nelson
    Department of Medicine, Division of Hematology Oncology, School of Medicine and Molecular Biology and Biochemistry, University of California, Irvine, CA 97697 4060, USA
    Breast Cancer Res Treat 82:169-83. 2003
  10. ncbi Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins
    Lia M Haynes
    National Centers for Immunization and Respiratory Diseases, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G 18, Atlanta, GA 30333
    Clin Vaccine Immunol 14:331-3. 2007

Research Grants

  1. Development of an VEE Replicon Vaccine Against Smallpox
    Kurt Kamrud; Fiscal Year: 2005

Collaborators

  • Jonathan O Rayner
  • Ryan L Vander Veen
  • Elizabeth A Reap
  • Chad Cecil
  • Jonathan Smith
  • Peter Pushko
  • John S Lee
  • Edward L Nelson
  • Bolyn Hubby
  • Kevin P Nishimoto
  • Lia M Haynes
  • Gregory J Babcock
  • Jeffrey D Chulay
  • Amanda K Laust
  • Jennifer Betts Oliver
  • Jennifer L Harcourt
  • Bruce K Burnett
  • Mary Reynolds
  • Laura Copp
  • Aubrey Watson
  • Donna M Ambrosino
  • Andrew Graham
  • Harold Alterson
  • Timothy M Uyeki
  • James A Comer
  • Larry J Anderson
  • Joel M Montgomery
  • Congrong Miao
  • Mai Quynh Le
  • Jordan Wagner
  • Daniel Bausch
  • Peter Berglund
  • Sergey A Dryga
  • William Thomas
  • Bryan Rivers
  • Kehui Wang
  • Whitney Lewis
  • Pamela Norberg
  • Thomas Ksiazek
  • Todd Talarico
  • Maureen Maughan
  • Sarah Negri

Detail Information

Publications10

  1. ncbi In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs
    Kurt I Kamrud
    AlphaVax, Inc, Research Triangle Park, North Carolina 27709, USA
    J Virol 84:7713-25. 2010
    ..These data provide the first example of miRNA-specific repression of alphavirus replicon and helper RNA replication and demonstrate the feasibility of miRNA targeting of expression vector helper functions that are provided in trans...
  2. ncbi Alphavirus replicon approach to promoterless analysis of IRES elements
    K I Kamrud
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709 0307, USA
    Virology 360:376-87. 2007
    ..The ability to modulate the level of expression from alphavirus vectors should extend the utility of these vectors in vaccine development...
  3. ncbi Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle
    K I Kamrud
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709, USA
    J Gen Virol 91:1723-7. 2010
    ....
  4. ncbi Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats
    Kurt I Kamrud
    AlphaVax, Inc, Research Triangle Park, North Carolina, United States of America
    PLoS ONE 3:e2709. 2008
    ..We examined VRP packaged in four different VEE GP coats for their ability to infect cells in vitro and to induce both humoral and cellular immune responses in vivo...
  5. ncbi Development and preclinical evaluation of an alphavirus replicon vaccine for influenza
    Bolyn Hubby
    AlphaVax, Inc, 2 Triangle Drive, Research Triangle Park, NC 27709, USA
    Vaccine 25:8180-9. 2007
    ..NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza...
  6. ncbi Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine
    Ryan L Vander Veen
    Harrisvaccines, Inc, Ames, IA 50010, USA
    Vaccine 30:1944-50. 2012
    ..In addition, vaccinated pigs develop both specific humoral and IFN-γ immune responses, and young pigs are protected against homologous influenza virus challenge...
  7. ncbi Alphavirus vectors and vaccination
    Jonathan O Rayner
    AlphaVax, Inc, P O Box 110307, Research Triangle Park, NC 27709 0307, USA
    Rev Med Virol 12:279-96. 2002
    ..In addition, as the alphavirus structural proteins are not expressed in vaccine recipients, antivector immune responses are generally minimal, allowing for multiple effective immunisations of the same individual...
  8. ncbi Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells
    Kevin P Nishimoto
    Molecular Biology and Biochemistry, School of Medicine, School of Biological Sciences, University of California, Irvine, Irvine, California 92697, USA
    Viral Immunol 20:88-104. 2007
    ..These studies support the demonstration of selective VRP tropism for human DCs and provide further insight into the biology of the VRP vector, its parent virus, and human DCs...
  9. ncbi Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model
    Edward L Nelson
    Department of Medicine, Division of Hematology Oncology, School of Medicine and Molecular Biology and Biochemistry, University of California, Irvine, CA 97697 4060, USA
    Breast Cancer Res Treat 82:169-83. 2003
    ..These data support the continued development and potential clinical application of this alphaviral replicon vector system and the use of appropriately designed target antigen sequences for anti-tumor immunotherapy...
  10. ncbi Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins
    Lia M Haynes
    National Centers for Immunization and Respiratory Diseases, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G 18, Atlanta, GA 30333
    Clin Vaccine Immunol 14:331-3. 2007
    ..These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies...

Research Grants2

  1. Development of an VEE Replicon Vaccine Against Smallpox
    Kurt Kamrud; Fiscal Year: 2005
    ....